PDE5 inhibitors could increase the effectiveness of existing HCC therapies by permitting additional immune cells into a tumor, thereby weakening the immune system's ability to suppress the tumor and restoring normal blood flow to the area surrounding the tumor. This evidence concerns the gene PDE5A and hepatocellular carcinoma.